INAB News
Archived Headlines
- Gamma-delta T cell biotech IN8bio revives $69 million IPO with new blank filing 03/31/21
- US IPO Weekly Recap: Postponements abound as DoorDash joins the IPO pipeline 11/13/20
- Cancer biotech IN8bio postpones $75 million IPO 11/13/20
- US IPO Week Ahead: Biotechs break the post-election ice in a 3 IPO week 11/06/20
- Cancer biotech IN8bio sets terms for $75 million IPO 11/05/20
See more
US IPO Weekly Recap: Biotechs pop and Robinhood flops in a record 20 IPO week
The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed,...read more
Gamma-delta T cell biotech IN8bio prices IPO at $10 low end
IN8bio, a Phase 1 oncology biotech developing allogeneic gamma-delta T cell therapies, raised $40 million by offering 4 million shares at $10, the low end of the range of $10 to $12. The company's pipeline contains lead candidates INB-200, which is currently...read more
US IPO Week Ahead: Robinhood’s billion-dollar deal headlines a 25 IPO week
Updated Monday, 7/26. After another week of record activity, the IPO market is expected to remain hot with 25 IPOs scheduled for the week ahead. If all scheduled IPOs begin trading as expected, it would be the busiest week for the US IPO market in...read more
Gamma-delta T cell biotech IN8bio relaunches $44 million IPO
IN8bio, a Phase 1 oncology biotech developing allogeneic gamma-delta T cell therapies, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $44 million by offering 4 million shares at a price range of $10 to $12. At the...read more